QuidelOrtho Corp logo

QuidelOrtho Corp(QDEL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$8.92
11/19/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for QDEL

11/19/2026: QDEL (1-star) is currently NOT-A-BUY. Pass it for now.

QuidelOrtho is a major global diagnostic testing and healthcare company operating across clinical labs, transfusion medicine, point-of-care, and molecular segments. The company's key strengths include its proprietary VITROS dry-slide technology, established installed instrument base, and leadership in rapid infectious disease tests. Its primary growth opportunity centers on expanding adoption and menu offerings for the Savanna molecular system. However, the company faces ongoing financial integration costs from the Ortho merger, post-pandemic testing revenue normalization, and intense competition from massive healthcare conglomerates. QuidelOrtho suits growth-oriented healthcare investors willing to tolerate near-term earnings volatility, with key developments to monitor including molecular platform adoption rates and margin enhancement initiatives.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitTop-line growth has moderated post-pandemic, making future growth heavily reliant on new platform adoption like Savanna.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive upturn signal given historical share price volatility.
Value investorMixed fitLow forward earnings multiples suggest potential value, but earnings variability and integration headwinds require careful scrutiny.
Dividend investorWeak fitThe company does not pay a dividend, focusing capital allocation on debt reduction and business reinvestment.
Low-risk investorWeak fitShare price volatility and ongoing integration execution risks limit suitability for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock has experienced wide swings reflecting shifting post-pandemic testing demand and earnings adjustments.
Valuation riskMediumForward valuation multiples appear modest, but headline earnings can be obscured by non-cash charges and restructuring costs.
Competition risk (large diagnostics conglomerates)HighQuidelOrtho contends with multi-billion-dollar medical giants possessing massive bundled lab service contracts.
Business qualityMedium / highThe company maintains strong underlying franchises in blood typing and rapid testing, though profitability has faced transitional pressures.
Dividend incomeLow / noneIncome-focused investors receive zero dividend yield from the stock.
Execution riskHighSuccessfully integrating Ortho operations and expanding new instrument placements execution is critical to financial recovery.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 656.62M USD
Price to earnings Ratio -
1Y Target Price 15
Price to earnings Ratio -
1Y Target Price 15
Volume (30-day avg) 2.5M shares
Beta 0.8
52 Weeks Range 8.88 - 35.58
Updated Date 11/19/2026
52 Weeks Range 8.88 - 35.58
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -5.39

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
50.0%
Active BUY / eligible
4 / 8
30-Day BUY Count Change
+2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -48.88%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/19/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
QDEL receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
QDEL has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+44.8%) is partially offset by weak cash generation (FCF margin -3.0%), slightly negative revenue growth (-1.9%), weak profitability (net margin -41.5%).

Financial Health Rating

★★★★★
QDEL's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 8.3%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is QDEL's strongest growth driver at +44.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+26.0%, solid) is also solid, while revenue growth (-1.9%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 122.7% and approximately 91.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.92%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 16.33%
FMR Inc 10.73%
Newtyn Management LLC 9.66%
Vanguard Portfolio Management, LLC 6.03%
American Century Companies Inc 5.72%

Unit Economics (Per $1K Revenue)

★★★★★
QDEL generates approximately $467 of gross profit, $-337 of operating income, and $-30 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -2.18% (Tax Credit)

Quantitative Style Profile

★★★★★
QDEL has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
LabsClinical chemistry and immunoassay instruments, reagents, and consumable test kits for hospital and commercial laboratories.Generates steady recurring revenue through reagent rentals and consumable test sales to hospital labs.
Transfusion MedicineDonor screening systems, blood typing instruments, and pre-transfusion testing automation software.Provides stable, highly regulated blood bank solutions that ensure safety across global blood supplies.
Point of CareRapid lateral-flow strips and Sofia fluorescent immunoassay tests for infectious diseases and respiratory viruses.Delivers high-margin diagnostic products widely used in urgent care clinics, pharmacies, and physician offices.
Molecular DiagnosticsAdvanced molecular PCR assays and the Savanna multiplex diagnostic instrument system.Represents an emerging technology pillar aimed at capturing advanced decentralized molecular testing demand.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When After Market
Estimate 0.18
Actual 0.31

Profitability

Profit Margin -14.24%
Operating Margin (TTM) 0.17%

Management Effectiveness

Return on Assets (TTM) 0.05%
Return on Equity (TTM) -19.29%

Valuation

Trailing PE -
Forward PE 9.59
Enterprise Value 3.61B
Price to Sales(TTM) 0.25
Enterprise Value 3.61B
Price to Sales(TTM) 0.25
Enterprise Value to Revenue 1.39
Enterprise Value to EBITDA 11.04
Shares Outstanding 68.61M
Shares Floating 62.41M
Shares Outstanding 68.61M
Shares Floating 62.41M
Percent Insiders 0.92
Percent Institutions 122.75

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.